AACE Pharmaceuticals distributed adulterated Lubricant PM Ointment made by CMO Brassica with CGMP violations and failed supplier qualification.
What happened
FDA inspected AACE's Fairfield, NJ facility from Nov 12 to 22, 2024, after finding CGMP violations at Brassica, its CMO for ophthalmic drugs. The Brassica inspection (Jan 15-19, 2024) found poor aseptic practices, fabricated microbiology records, and microbial contamination. AACE imported and distributed Lubricant PM Ointment from Brassica despite knowing 2020 deficiencies, and its quality unit failed to adequately qualify the CMO.
What FDA found
Quality unit lacked adequate supplier qualification procedures to ensure CMO-made drugs were CGMP-compliant before distribution.
21 CFR 211.22(a)Released Lubricant PM Ointment for distribution without adequate procedures to ensure quality attributes.
21 CFR 211.22(a)Qualified Brassica as an approved CMO despite known CGMP deficiencies and requalified without evaluating corrective actions.
21 CFR 211.22(a)Received adulterated drugs in interstate commerce and delivered or offered them for delivery.
FD&C Act section 301(c), 21 U.S.C. 331(c)Introduced adulterated drugs into interstate commerce.
FD&C Act section 301(a), 21 U.S.C. 331(a)
What FDA wants
Provide a detailed plan to ensure you do not receive or deliver adulterated drugs, including evaluating current CMOs, improving qualification procedures, and conducting periodic audits; clarify whether you intend to distribute ophthalmic or sterile drugs for the U.S. market. Respond in writing within 15 working days.
Who should pay attention
- companies that distribute or private-label ophthalmic drugs made by contract manufacturers
- drug manufacturers using CMOs for sterile products
- quality teams responsible for supplier qualification and CMO oversight
This is a summary. Read the original letter on fda.gov.